About this trial
Lynch syndrome is a genetic condition that increases cancer risk. The public health impact of genetic testing for disease prevention hinges on cascade screening, which is the systematic identification and testing of blood relatives after a family member has been diagnosed with a genetic condition. Despite its importance in disease prevention, only half of first-degree relatives of individuals with Lynch syndrome undergo cascade screening. To address this gap, the study will pilot test an online version of Let's Talk, a novel intervention designed to support and promote cascade screening. This intervention tool is designed to support and encourage more family members to get screened. The purpose of this study aim is to assess the feasibility of the online Let's Talk tool in clinical use by examining implementation and effectiveness outcomes related to the use of the planning tool across three clinics at a large academic-affiliated medical center with patients (n=15) seen by one of five genetic counselors (n=5).
Eligibility criteria
Qualifiers
Written informed consent obtained to participate in the study.
Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.
Age ≥ 18 years at the time of consent.
Written informed consent obtained to participate in the study.
Disqualifiers
The patient has already notified all relatives about their diagnosis with Lynch syndrome.
Genetic Counselor is not employed.
Trial design
Treatments tested in this trial
- Let's Talk Genetics Providers
- Let's Talk Patients
Treatment groups
Sponsors and collaborators
UNC Lineberger Comprehensive Cancer Center
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Human Genome Research Institute (NHGRI)
Collaborator